US pharma giant Merck & Co (NYSE: MRK) on Tuesday said it has agreed to buy Israel-based drugmaker cCAM Biotherapeutics for as much as $605 million in a bid to expand its immuno-oncology portfolio.
President of Merck Research Laboratories, Roger Perlmutter said: "We continue to strengthen our portfolio of immunotherapeutic candidates through strategic collaborations and acquisitions."
Under the agreed terms, Merck will pay an upfront amount of $95 million in cash to cCAM. In addition, cCAM will also receive a total of up to $510 million in various milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze